Study · Randomized controlled trial · n = 316 · 2018

33 results

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A

Lancet (London, England)4 Oct 2018Cited by 651 (Europe PMC)

PMID30293770DOI10.1016/s0140-6736(18)32260-8PepBankPUB-30293770

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study33

30 results from studies that gave the peptide. 30 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in a phase 2 trial, LY3298176 (tirzepatide) lowered HbA1c from baseline at 26 weeks in a dose-dependent way (-1·06%, -1·73%, -1·89% and -1·94% with 1, 5, 10 and 15 mg) versus -0·06% with placebo.
In plain wordsIn adults with type 2 diabetes, tirzepatide lowered long-term blood sugar (HbA1c) more than placebo, and higher doses lowered it more.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline to week 26 vs placebo
Study
n = 316
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Mean changes from baseline in HbA_1c with LY3298176 were -1·06% for 1 mg, -1·73% for 5 mg, -1·89% for 10 mg, and -1·94% for 15 mg, compared with -0·06% for placebo
3 context sentences(design, population, supporting numbers)
Summary · context
posterior mean differences [80% credible set] vs placebo: -1·00% [-1·22 to -0·79] for 1 mg, -1·67% [-1·88 to -1·46] for 5 mg, -1·83% [-2·04 to -1·61] for 10 mg, and -1·89% [-2·11 to -1·67] for 15 mg
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Summary · context
Because two participants did not receive treatment, the modified intention-to-treat and safety populations included 316 participants.
Report a problemFND-3029377001
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, compared with dulaglutide (-1·21%), the posterior mean difference in HbA1c change at 26 weeks was -0·52%, -0·67% and -0·73% with LY3298176 (tirzepatide) 5, 10 and 15 mg, and 0·15% with 1 mg (80% credible sets: -0·72 to -0·31, -0·89 to -0·46, -0·95 to -0·52, and -0·08 to 0·38).
In plain wordsIn adults with type 2 diabetes, tirzepatide at 5, 10 and 15 mg lowered long-term blood sugar (HbA1c) more than dulaglutide.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline to week 26 vs dulaglutide
Study
n = 316
Comparator
Dulaglutide 1·5 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Compared with dulaglutide (-1·21%) the posterior mean differences (80% credible set) for change in HbA_1c from baseline to 26 weeks with the LY3298176 doses were 0·15% (-0·08 to 0·38) for 1 mg, -0·52% (-0·72 to -0·31) for 5 mg, -0·67% (-0·89 to -0·46) for 10 mg, and -0·73% (-0·95 to -0·52) for 15 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Summary · context
Because two participants did not receive treatment, the modified intention-to-treat and safety populations included 316 participants.
Report a problemFND-3029377002
03HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, the HbA1c difference between LY3298176 1 mg and dulaglutide had an 80% credible set that crossed zero.
In plain wordsIn patients with diabetes, the estimated HbA1c difference between LY3298176 1 mg and dulaglutide included zero in its 80% credible range.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHbA1c versus LY3298176 1 mg
Study
n: not reported in source
Comparator
LY3298176 1 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.21%
dulaglutide
Posterior mean difference in HbA1c
0.15%
LY3298176 1 mg versus dulaglutide, 80% credible set -0.08 to 0.38
80% credible set
−0.08 to 0.38%
LY3298176 1 mg versus dulaglutide
Source sentences
Summary
Compared with dulaglutide (-1·21%) the posterior mean differences (80% credible set) for change in HbA_1c from baseline to 26 weeks with the LY3298176 doses were 0·15% (-0·08 to 0·38) for 1 mg
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377018
04HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide reduced HbA1c less than LY3298176 5 mg.
In plain wordsIn patients with diabetes, dulaglutide reduced HbA1c less than LY3298176 5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c versus LY3298176 5 mg
Study
n: not reported in source
Comparator
LY3298176 5 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.21%
dulaglutide
Posterior mean difference in HbA1c
−0.52%
LY3298176 5 mg versus dulaglutide, 80% credible set -0.72 to -0.31
80% credible set
−0.72 to −0.31%
LY3298176 5 mg versus dulaglutide
Source sentences
Summary
Compared with dulaglutide (-1·21%) the posterior mean differences (80% credible set) for change in HbA_1c from baseline to 26 weeks with the LY3298176 doses were 0·15% (-0·08 to 0·38) for 1 mg, -0·52% (-0·72 to -0·31) for 5 mg, -0·67% (-0·89 to -0·46) for 10 mg, and -0·73% (-0·95 to -0·52) for 15 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377019
05HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide reduced HbA1c less than LY3298176 10 mg.
In plain wordsIn patients with diabetes, dulaglutide reduced HbA1c less than LY3298176 10 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c versus LY3298176 10 mg
Study
n: not reported in source
Comparator
LY3298176 10 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.21%
dulaglutide
Posterior mean difference in HbA1c
−0.67%
LY3298176 10 mg versus dulaglutide, 80% credible set -0.89 to -0.46
80% credible set
−0.89 to −0.46%
LY3298176 10 mg versus dulaglutide
Source sentences
Summary
Compared with dulaglutide (-1·21%) the posterior mean differences (80% credible set) for change in HbA_1c from baseline to 26 weeks with the LY3298176 doses were 0·15% (-0·08 to 0·38) for 1 mg, -0·52% (-0·72 to -0·31) for 5 mg, -0·67% (-0·89 to -0·46) for 10 mg, and -0·73% (-0·95 to -0·52) for 15 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377020
06HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide reduced HbA1c less than LY3298176 15 mg.
In plain wordsIn patients with diabetes, dulaglutide reduced HbA1c less than LY3298176 15 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c versus LY3298176 15 mg
Study
n: not reported in source
Comparator
LY3298176 15 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.21%
dulaglutide
Posterior mean difference in HbA1c
−0.73%
LY3298176 15 mg versus dulaglutide, 80% credible set -0.95 to -0.52
80% credible set
−0.95 to −0.52%
LY3298176 15 mg versus dulaglutide
Source sentences
Summary
Compared with dulaglutide (-1·21%) the posterior mean differences (80% credible set) for change in HbA_1c from baseline to 26 weeks with the LY3298176 doses were 0·15% (-0·08 to 0·38) for 1 mg, -0·52% (-0·72 to -0·31) for 5 mg, -0·67% (-0·89 to -0·46) for 10 mg, and -0·73% (-0·95 to -0·52) for 15 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377021
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, 33% to 90% of patients on LY3298176 (tirzepatide) reached an HbA1c below 7·0% at 26 weeks, versus 52% on dulaglutide and 12% on placebo.
In plain wordsIn adults with type 2 diabetes, 33% to 90% of people on tirzepatide reached an HbA1c below 7% across doses, versus 12% on placebo.
Peptide
Tirzepatide
Outcome
IncreaseProportion with HbA1c below 7·0% at week 26
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Patients with HbA1c below 7·0%
33 to 90%
LY3298176 groups (range)
Patients with HbA1c below 7·0%
52%
dulaglutide
Patients with HbA1c below 7·0%
12%
placebo
Source sentences
Summary
At 26 weeks, 33-90% of patients treated with LY3298176 achieved the HbA_1c target of less than 7·0% (vs 52% with dulaglutide, 12% with placebo)
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints, measured in the mITT on treatment dataset
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377003
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, 15% to 82% of patients on LY3298176 (tirzepatide) reached the 6·5% HbA1c target at 26 weeks (worded "at least 6·5%" in the abstract), versus 39% on dulaglutide and 2% on placebo.
In plain wordsIn adults with type 2 diabetes, 15% to 82% of people on tirzepatide reached a set HbA1c target across doses, versus 2% on placebo.
Peptide
Tirzepatide
Outcome
IncreaseProportion reaching the 6·5% HbA1c target at week 26
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Patients reaching the 6·5% HbA1c target
15 to 82%
LY3298176 groups (range)
Patients reaching the 6·5% HbA1c target
39%
dulaglutide
Patients reaching the 6·5% HbA1c target
2%
placebo
Source sentences
Summary
15-82% achieved the HbA_1c target of at least 6·5% (vs 39% with dulaglutide, 2% with placebo)
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints, measured in the mITT on treatment dataset
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377004
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, fasting plasma glucose changed by -0·4 to -3·4 mmol/L with LY3298176 (tirzepatide) across doses, versus 0·9 mmol/L with placebo and -1·2 mmol/L with dulaglutide (no test reported).
In plain wordsIn adults with type 2 diabetes, fasting blood sugar fell with tirzepatide across doses, while it rose with placebo.
Peptide
Tirzepatide
Outcome
DecreaseFasting plasma glucose change
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes in fasting plasma glucose ranged from -0·4 mmol/L to -3·4 mmol/L for LY3298176 (vs 0·9 mmol/L for placebo, -1·2 mmol/L for dulaglutide).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints, measured in the mITT on treatment dataset
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377005
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, mean bodyweight changed by -0·9 to -11·3 kg with LY3298176 (tirzepatide) across doses, versus -0·4 kg with placebo and -2·7 kg with dulaglutide (no test reported).
In plain wordsIn adults with type 2 diabetes, weight loss with tirzepatide ranged from 0·9 to 11·3 kg across doses, versus 0·4 kg with placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes in mean bodyweight ranged from -0·9 kg to -11·3 kg for LY3298176 (vs -0·4 kg for placebo, -2·7 kg for dulaglutide).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints, measured in the mITT on treatment dataset
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377006
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, 14% to 71% of patients on LY3298176 (tirzepatide) lost at least 5% of body weight at 26 weeks, versus 22% on dulaglutide and 0% on placebo.
In plain wordsIn type 2 diabetes, 14% to 71% of people on tirzepatide lost at least 5% of their weight across doses; none on placebo did.
Peptide
Tirzepatide
Outcome
IncreaseProportion with at least 5% weight loss at week 26
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Patients with at least 5% weight loss
14 to 71%
LY3298176 groups (range)
Patients with at least 5% weight loss
22%
dulaglutide
Patients with at least 5% weight loss
0%
placebo
Source sentences
Summary
At 26 weeks, 14-71% of those treated with LY3298176 achieved the weight loss target of at least 5% (vs 22% with dulaglutide, 0% with placebo) and 6-39% achieved the weight loss target of at least 10% (vs 9% with dulaglutide, 0% with placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints, measured in the mITT on treatment dataset
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377007
12HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, 6% to 39% of patients on LY3298176 (tirzepatide) lost at least 10% of body weight at 26 weeks, versus 9% on dulaglutide and 0% on placebo.
In plain wordsIn type 2 diabetes, 6% to 39% of people on tirzepatide lost at least 10% of their weight across doses; none on placebo did.
Peptide
Tirzepatide
Outcome
IncreaseProportion with at least 10% weight loss at week 26
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Patients with at least 10% weight loss
6 to 39%
LY3298176 groups (range)
Patients with at least 10% weight loss
9%
dulaglutide
Patients with at least 10% weight loss
0%
placebo
Source sentences
Summary
At 26 weeks, 14-71% of those treated with LY3298176 achieved the weight loss target of at least 5% (vs 22% with dulaglutide, 0% with placebo) and 6-39% achieved the weight loss target of at least 10% (vs 9% with dulaglutide, 0% with placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints, measured in the mITT on treatment dataset
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377008
13HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, waist circumference changed by -2·1 to -10·2 cm with LY3298176 (tirzepatide) across doses, versus -1·3 cm with placebo and -2·5 cm with dulaglutide (no test reported).
In plain wordsIn adults with type 2 diabetes, waist size fell by 2·1 to 10·2 cm across tirzepatide doses, versus 1·3 cm with placebo.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference change
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes in waist circumference ranged from -2·1 cm to -10·2 cm for LY3298176 (vs -1·3 cm for placebo, -2·5 cm for dulaglutide).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints, measured in the mITT on treatment dataset
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377009
14HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, total cholesterol changed by 0·2 to -0·3 mmol/L with LY3298176 (tirzepatide) across doses, versus 0·3 mmol/L with placebo and -0·2 mmol/L with dulaglutide (no test reported).
In plain wordsIn adults with type 2 diabetes, total cholesterol changes with tirzepatide ranged from a rise of 0·2 to a fall of 0·3 mmol/L across doses.
Peptide
Tirzepatide
Outcome
MixedTotal cholesterol change
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes in total cholesterol ranged from 0·2 mmol/L to -0·3 mmol/L for LY3298176 (vs 0·3 mmol/L for placebo, -0·2 mmol/L for dulaglutide).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints, measured in the mITT on treatment dataset
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377010
15HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, changes in HDL and LDL cholesterol did not differ between the LY3298176 (tirzepatide) and placebo groups.
In plain wordsIn adults with type 2 diabetes, HDL and LDL cholesterol changes with tirzepatide did not differ from placebo.
Peptide
Tirzepatide
Outcome
No significant changeHDL and LDL cholesterol change
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes in HDL or LDL cholesterol did not differ between the LY3298176 and placebo groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints, measured in the mITT on treatment dataset
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377011
16HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, triglyceride concentration changed by 0 to -0·8 mmol/L with LY3298176 (tirzepatide) across doses, versus 0·3 mmol/L with placebo and -0·3 mmol/L with dulaglutide (no test reported).
In plain wordsIn type 2 diabetes, triglycerides changed from 0 to a fall of 0·8 mmol/L across tirzepatide doses, versus a rise of 0·3 with placebo.
Peptide
Tirzepatide
Outcome
DecreaseTriglyceride change
Study
n: not reported in source
Comparator
Placebo and dulaglutide
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes in triglyceride concentration ranged from 0 mmol/L to -0·8 mmol/L for LY3298176 (vs 0·3 mmol/L for placebo, -0·3 mmol/L for dulaglutide).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints, measured in the mITT on treatment dataset
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377012
17HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, 52% receiving dulaglutide versus 12% receiving placebo achieved HbA1c below 7.0% at 26 weeks.
In plain wordsIn patients with diabetes, 52% on dulaglutide and 12% on placebo reached an HbA1c below 7.0%.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedHbA1c below target
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Proportion with HbA1c <7.0%
52%
dulaglutide
Proportion with HbA1c <7.0%
12%
placebo
Source sentences
Summary
At 26 weeks, 33-90% of patients treated with LY3298176 achieved the HbA_1c target of less than 7·0% (vs 52% with dulaglutide, 12% with placebo) and 15-82% achieved the HbA_1c target of at least 6·5% (vs 39% with dulaglutide, 2% with placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377022
18HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, 39% receiving dulaglutide versus 2% receiving placebo achieved the second HbA1c target at 26 weeks, which the abstract words inconsistently (methods: 6.5% or lower, results: at least 6.5%).
In plain wordsIn patients with diabetes, 39% on dulaglutide and 2% on placebo reached the second HbA1c target, which the abstract words inconsistently.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedSecond HbA1c target as reported
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Proportion reaching second HbA1c target (6.5%)
39%
dulaglutide
Proportion reaching second HbA1c target (6.5%)
2%
placebo
Source sentences
Summary
At 26 weeks, 33-90% of patients treated with LY3298176 achieved the HbA_1c target of less than 7·0% (vs 52% with dulaglutide, 12% with placebo) and 15-82% achieved the HbA_1c target of at least 6·5% (vs 39% with dulaglutide, 2% with placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
proportion of patients reaching the HbA_1c target (≤6·5% and <7·0%) from baseline to weeks 12 and 26
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377023
19HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, fasting plasma glucose changed by -1.2 mmol/L with dulaglutide versus 0.9 mmol/L with placebo.
In plain wordsIn patients with diabetes, fasting blood glucose fell with dulaglutide and changed in the other direction with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting plasma glucose change
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Fasting plasma glucose change
−1.2 mmol/L
dulaglutide
Fasting plasma glucose change
0.9 mmol/L
placebo
Source sentences
Summary
Changes in fasting plasma glucose ranged from -0·4 mmol/L to -3·4 mmol/L for LY3298176 (vs 0·9 mmol/L for placebo, -1·2 mmol/L for dulaglutide).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377024
20HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, 22% receiving dulaglutide versus 0% receiving placebo achieved weight loss of at least 5% at 26 weeks.
In plain wordsIn patients with diabetes, 22% on dulaglutide and 0% on placebo lost at least 5% of their weight.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedWeight loss of at least 5%
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Proportion with weight loss of at least 5%
22%
dulaglutide
Proportion with weight loss of at least 5%
0%
placebo
Source sentences
Summary
At 26 weeks, 14-71% of those treated with LY3298176 achieved the weight loss target of at least 5% (vs 22% with dulaglutide, 0% with placebo) and 6-39% achieved the weight loss target of at least 10% (vs 9% with dulaglutide, 0% with placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377026
21HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, 9% receiving dulaglutide versus 0% receiving placebo achieved weight loss of at least 10% at 26 weeks.
In plain wordsIn patients with diabetes, 9% on dulaglutide and 0% on placebo lost at least 10% of their weight.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedWeight loss of at least 10%
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Proportion with weight loss of at least 10%
9%
dulaglutide
Proportion with weight loss of at least 10%
0%
placebo
Source sentences
Summary
At 26 weeks, 14-71% of those treated with LY3298176 achieved the weight loss target of at least 5% (vs 22% with dulaglutide, 0% with placebo) and 6-39% achieved the weight loss target of at least 10% (vs 9% with dulaglutide, 0% with placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377027
22HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, total cholesterol changed by -0.2 mmol/L with dulaglutide versus 0.3 mmol/L with placebo.
In plain wordsIn patients with diabetes, total cholesterol fell with dulaglutide and changed in the other direction with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTotal cholesterol change
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Total cholesterol change
−0.2 mmol/L
dulaglutide
Total cholesterol change
0.3 mmol/L
placebo
Source sentences
Summary
Changes in total cholesterol ranged from 0·2 mmol/L to -0·3 mmol/L for LY3298176 (vs 0·3 mmol/L for placebo, -0·2 mmol/L for dulaglutide).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377029
23HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, triglycerides changed by -0.3 mmol/L from baseline with dulaglutide, versus 0.3 mmol/L with placebo.
In plain wordsIn patients with diabetes, triglycerides fell from baseline with dulaglutide, compared with a change of 0.3 mmol/L with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTriglyceride change
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Triglyceride change
−0.3 mmol/L
dulaglutide
Triglyceride change
0.3 mmol/L
placebo
Source sentences
Summary
Changes in triglyceride concentration ranged from 0 mmol/L to -0·8 mmol/L for LY3298176 (vs 0·3 mmol/L for placebo, -0·3 mmol/L for dulaglutide).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377030
24HumanRandomized controlled trialSafety outcome
In a phase 2 trial in adults with type 2 diabetes, 13 (4%) of 316 participants across the six treatment groups had 23 serious adverse events in total.
In plain wordsIn this 26-week trial in adults with type 2 diabetes, 13 of 316 people across all six groups had serious adverse events.
Peptide
Tirzepatide
Outcome
Not applicableSerious adverse events
Study
n = 316
Outcome group
Adverse events · Whole body
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Participants with serious adverse events
13 participants
all six treatment groups
Serious adverse events
23 events
all six treatment groups
Source sentences
Summary
13 (4%) of 316 participants across the six treatment groups had 23 serious adverse events in total.
1 context sentence(design, population, supporting numbers)
Summary · context
Because two participants did not receive treatment, the modified intention-to-treat and safety populations included 316 participants.
Report a problemFND-3029377013
25HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, the incidence of gastrointestinal events was dose-related with LY3298176 (tirzepatide): 23·1%, 32·7%, 51·0% and 66·0% at 1, 5, 10 and 15 mg, versus 42·6% with dulaglutide and 9·8% with placebo; most events were mild to moderate and transient.
In plain wordsIn adults with type 2 diabetes, stomach and gut side effects became more common as the tirzepatide dose rose, mostly mild to moderate.
Peptide
Tirzepatide
Outcome
IncreaseGastrointestinal events (nausea, diarrhoea, vomiting)
Study
n = 316
Comparator
Placebo and dulaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
The incidence of gastrointestinal events was dose-related (23·1% for 1 mg LY3298176, 32·7% for 5 mg LY3298176, 51·0% for 10 mg LY3298176, and 66·0% for 15 mg LY3298176, 42·6% for dulaglutide, 9·8% for placebo); most events were mild to moderate in intensity and transient.
1 context sentence(design, population, supporting numbers)
Summary · context
Because two participants did not receive treatment, the modified intention-to-treat and safety populations included 316 participants.
Report a problemFND-3029377014
26HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, decreased appetite was the second most common adverse event: 3·8%, 20·0%, 25·5% and 18·9% at 1, 5, 10 and 15 mg of LY3298176 (tirzepatide), versus 5·6% with dulaglutide and 2·0% with placebo.
In plain wordsIn adults with type 2 diabetes, reduced appetite was the second most common side effect of tirzepatide.
Peptide
Tirzepatide
Outcome
IncreaseDecreased appetite
Study
n = 316
Comparator
Placebo and dulaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Decreased appetite was the second most common adverse event (3·8% for 1 mg LY3298176, 20·0% for 5 mg LY3298176, 25·5% for 10 mg LY3298176, 18·9% for 15 mg LY3298176, 5·6% for dulaglutide, 2·0% for placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Because two participants did not receive treatment, the modified intention-to-treat and safety populations included 316 participants.
Report a problemFND-3029377015
27HumanRandomized controlled trialSafety outcome
In this 26-week phase 2 trial in adults with type 2 diabetes, there were no reports of severe hypoglycaemia.
In plain wordsIn this 26-week trial in adults with type 2 diabetes, no severe low blood sugar events were reported.
Peptide
Tirzepatide
Outcome
Not applicableSevere hypoglycaemia
Study
n = 316
Outcome group
Adverse events · Metabolic and weight
Studied dose
1 mg, 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
There were no reports of severe hypoglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Because two participants did not receive treatment, the modified intention-to-treat and safety populations included 316 participants.
Report a problemFND-3029377016
28HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, gastrointestinal events occurred in 42.6% with dulaglutide and 9.8% with placebo.
In plain wordsIn patients with diabetes, digestive side effects occurred in 42.6% with dulaglutide and 9.8% with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableGastrointestinal events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Gastrointestinal event incidence
42.6%
dulaglutide
Gastrointestinal event incidence
9.8%
placebo
Source sentences
Summary
The incidence of gastrointestinal events was dose-related (23·1% for 1 mg LY3298176, 32·7% for 5 mg LY3298176, 51·0% for 10 mg LY3298176, and 66·0% for 15 mg LY3298176, 42·6% for dulaglutide, 9·8% for placebo); most events were mild to moderate in intensity and transient.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377035
29HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, decreased appetite occurred in 5.6% with dulaglutide and 2.0% with placebo.
In plain wordsIn patients with diabetes, decreased appetite was reported by 5.6% with dulaglutide and 2.0% with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDecreased appetite
Study
n: not reported in source
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Decreased appetite incidence
5.6%
dulaglutide
Decreased appetite incidence
2%
placebo
Source sentences
Summary
Decreased appetite was the second most common adverse event (3·8% for 1 mg LY3298176, 20·0% for 5 mg LY3298176, 25·5% for 10 mg LY3298176, 18·9% for 15 mg LY3298176, 5·6% for dulaglutide, 2·0% for placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377036
30HumanRandomized controlled trialSafety outcome
In patients with diabetes, no severe hypoglycaemia occurred in the trial, including the dulaglutide arm.
In plain wordsNo patients had severe low blood sugar in the trial, including those who received dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSevere hypoglycaemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.5 mg weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
There were no reports of severe hypoglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
Report a problemFND-3029377037

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

31HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes, HbA1c fell by 1.21% with dulaglutide and by 0.06% with placebo.
In plain wordsIn patients with diabetes, HbA1c decreased in both the dulaglutide and placebo groups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−1.21%
dulaglutide
HbA1c change
−0.06%
placebo
Source sentences
Summary
Compared with dulaglutide (-1·21%)
Summary
compared with -0·06% for placebo
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3029377017
32HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes, mean bodyweight fell by 2.7 kg with dulaglutide and by 0.4 kg with placebo.
In plain wordsIn patients with diabetes, mean bodyweight decreased in both the dulaglutide and placebo groups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBodyweight change
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
Bodyweight change
−2.7 kg
dulaglutide
Bodyweight change
−0.4 kg
placebo
Source sentences
Summary
Changes in mean bodyweight ranged from -0·9 kg to -11·3 kg for LY3298176 (vs -0·4 kg for placebo, -2·7 kg for dulaglutide).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3029377025
33HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes, waist circumference fell by 2.5 cm with dulaglutide and by 1.3 cm with placebo.
In plain wordsIn patients with diabetes, waist circumference decreased in both the dulaglutide and placebo groups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWaist circumference change
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Measurements
Waist circumference change
−2.5 cm
dulaglutide
Waist circumference change
−1.3 cm
placebo
Source sentences
Summary
Changes in waist circumference ranged from -2·1 cm to -10·2 cm for LY3298176 (vs -1·3 cm for placebo, -2·5 cm for dulaglutide).
1 context sentence(design, population, supporting numbers)
Summary · context
In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3029377028

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 4NCT06606821

The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

Tina Vilsbølln = 1241 Oct 2024 to est. 1 Aug 2028

Coronary Artery Disease · Coronary Microvascular Dysfunction · Overweight or Obesity · Stable Angina Pectoris · Chronic Coronary Artery Disease · Atherosclerosis Cardiovascular Disease

Trial page ClinicalTrials.govUpdated 22 May 2025

CompletedPhase 2Results postedNCT03131687

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 31824 May 2017 to 1 Aug 2018

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 20 Aug 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
9 Oct 2026, 12:39 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.